In addition to MITF, other amplified and overexpressed genes are HER2 in 15%–20% of invasive breast carcinomas [61], MYC in 15-20% of breast cancer [62] and several hematological malignancies [63], EGFR in squamous cell carcinomas [64], MDM2 in several cancer type [65]. This evidence concerns the gene ERBB2 and cancer.